Paper Details

  1. Home
  2. Paper Details

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Author: AltmanJessica K, CortesJorge E, ForanJames M, PratzKeith W, TallmanMartin S, TroneDenise

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and tolerability of quizartinib, a FLT3 inhibitor, in combination with standard of care chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML).
Paper Details　
Original Abstract of the Article :
Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/consolidation chemotherapy. Quizartinib is a select...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586071/

データ提供：米国国立医学図書館（NLM）

Phase 1 Study of Quizartinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia

This study explores the challenging terrain of acute myeloid leukemia (AML), a type of cancer that affects the bone marrow. The researchers are like scientists searching for a way to effectively treat AML, particularly in patients with FLT3-ITD mutations, which are linked to a higher risk of relapse and poorer survival. They conducted a phase 1 trial to investigate the safety and effectiveness of quizartinib, a drug targeting the FLT3 protein, when combined with standard chemotherapy. The results show that quizartinib was well-tolerated in combination with chemotherapy and achieved significant responses in a majority of patients.

A New Oasis in AML Treatment: The Potential of Quizartinib in Combination with Chemotherapy

This study provides promising evidence for the potential of quizartinib as a valuable tool in the fight against AML. The authors found that quizartinib was well-tolerated in combination with chemotherapy and resulted in significant responses in a majority of patients. This research represents a significant step forward in the treatment of AML, particularly for patients with FLT3-ITD mutations.

Navigating the Desert of AML: A Path Towards More Effective Treatments

This study offers a beacon of hope in the vast desert of AML research, providing evidence for a new and potentially more effective treatment approach. It highlights the potential of quizartinib, a drug targeting the FLT3 protein, to improve outcomes for individuals with AML, particularly those with FLT3-ITD mutations. This research is like finding a hidden oasis in the vast desert of AML treatment, offering a new and potentially more effective way to manage this challenging condition.

Dr.Camel's Conclusion

This study provides promising evidence for the potential of quizartinib in combination with chemotherapy for treating AML, particularly in patients with FLT3-ITD mutations. It's like finding a wellspring of hope in the vast desert of AML research, suggesting that quizartinib could lead to more effective treatment strategies and improved outcomes for patients.

Date :
  1. Date Completed 2018-12-11
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

29139135

DOI: Digital Object Identifier

PMC6586071

Related Literature

Article Analysis
・Effects of quizartinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.